Leila Montaser Montaser Kouhsari, MD
Neurology · Boston
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Brigham and Womens Physicians Organization Inc · 2,931 clinicians in this group
Hospitals listed: Brigham and Women'S Hospital · Newton-Wellesley Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kouhsari’s office at (855) 278-8009 to ask if they take your plan before you enroll.
California Medical Board record
Licence A159938 · Current
Licensed to practise in California · since 2018 · expires 2026-12-31 · Iran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Brigham and Women'S HospitalBoston, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mass General Brigham, which runs 15 hospitals in 2 statesHome of Dana-Farber/Harvard Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.711, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.596, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.505, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.51, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 0.9) · 2,432 cases, Jan 2024 – Dec 2024
- Newton-Wellesley HospitalNewton, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mass General Brigham, which runs 15 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.38 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.387, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 2,271 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Brigham and Women'S Hospital
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.711 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.596 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.505 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.51 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 0.9) · 2,432 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.69 (0.12 to 1.26) · 6,008 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.74 to 1.01) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.29 (133.21 to 183.36) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 365 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.1 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.7 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 697 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 456 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 6,699 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0.01 to 0.29) · 21,284 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.13 to 0.42) · 24,178 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.49 (3.47 to 5.51) · 9,415 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.37 (1.52 to 3.21) · 5,676 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.23 to 2.88) · 8,589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.32 (5.06 to 9.58) · 5,122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.49 (3.06 to 5.92) · 5,826 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.31 (0.19 to 2.43) · 2,520 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0.05 to 0.63) · 21,256 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 384 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.332 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.684 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 576 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 1,117 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.9 · 1,164 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.7 · 758 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 721 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3 to 7.2) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 7.5 (5.3 to 10.9) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 371 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.5 (9.5 to 14) · 5,029 cases | No different | Jan 2022 – Dec 2024 |
What patients said (666 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Newton-Wellesley Hospital
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.38 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.387 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 2,271 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.89 (0 to 1.77) · 2,111 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 144.57 (88.9 to 200.25) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 179 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 81 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.1 · 1,073 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 915 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.2 · 250 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2 · 4,630 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 12,256 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.13 to 0.49) · 12,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.67 (0.84 to 4.5) · 2,407 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 1,431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.21 (0.8 to 3.62) · 2,330 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.7 (0 to 11) · 1,382 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.12 (0.82 to 7.42) · 1,361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.28 (0 to 0.88) · 9,733 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 322 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.062 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.676 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.535 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.316 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 29 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.4 · 1,081 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.8 · 1,196 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 14.1 · 986 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.6 · 920 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3.1 to 6.6) · 235 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.3 to 14.1) · 235 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 196 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.8 to 14.9) · 4,203 cases | No different | Jan 2022 – Dec 2024 |
What patients said (644 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 1 |
| Recommend hospital | 5 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$46,683
Medicare paid this office $46,683 for 170 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 106 | $19,051 | $119 |
| New patient visit (60+ min) | 103 | $14,932 | $145 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 129 | $6,960 | $26 |
| Long return visit (40+ min) | 13 | $2,675 | $149 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 87 | $1,473 | $14 |
Who their Medicare patients are
170 Original Medicare patients in 2024. Average age 76 · Women 51% · Also on Medicaid 13% · Health risk score 1.36. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 69% · Depression 42% · Dementia 30% · Coronary heart disease 24% · Chronic kidney disease 22% · Diabetes 21% · Cancer 19% · Atrial fibrillation 18% · Heart failure 14% · COPD 11% · Stroke 11%.
The office billed $239,928, Medicare allowed $59,601 and paid $46,683; for 692 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 170 | 692 | 76 | 1.36 | $239,928 | $46,683 |
| 2023 | 181 | 272 | 75 | 1.53 | $134,295 | $22,956 |
| 2022 | 345 | 685 | 75 | 1.51 | $226,023 | $69,067 |
| 2021 | 300 | 638 | 74 | 1.50 | $234,086 | $67,092 |
| 2020 | 87 | 114 | 73 | 1.31 | $44,149 | $13,935 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 111 | $13,240 | $104 |
| Return visit (30+ min) | 58 | $4,942 | $73 |
| New patient visit (60+ min) | 17 | $2,643 | $155 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $596 | $27 |
2022: 7 services
| Long return visit (40+ min) | 281 | $48,887 | $111 |
| Return visit (30+ min) | 92 | $8,677 | $86 |
| New patient visit (60+ min) | 25 | $3,695 | $148 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 15 | $3,139 | $98 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 16 | $1,016 | $41 |
| Short return visit (20+ min) | 16 | $971 | $61 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 11 | $444 | $28 |
2021: 4 services
| Long return visit (40+ min) | 262 | $53,408 | $121 |
| New patient visit (60+ min) | 41 | $6,086 | $148 |
| Return visit (30+ min) | 24 | $2,420 | $93 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 47 | $2,172 | $29 |
2020: 2 services
| New patient visit (60+ min) | 49 | $7,619 | $155 |
| Long return visit (40+ min) | 43 | $5,395 | $104 |
Medicaid work
$328 in 2022
Medicaid paid $328 for 12 billed services this clinician did in 2022, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 12 | $328 |
| 2022 | 12 | 1 | 12 | $328 |
| 2021 | 45 | 1 | 17 | $1,033 |
See the largest Medicaid services in earlier years
2021
| Long return visit (40+ min) | 45 | $1,033 |
Drugs they prescribed that Part D paid
$108,329
Pharmacies billed $108,329 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 475) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
444 generic and 31 brand-name prescriptions · $108,329 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 12 | $20,741 | $1,728 |
| Carbidopa-Levodopa | None | 124 | $3,046 | $25 |
| Carbidopa-Levodopa Er | None | 59 | $2,931 | $50 |
| Amantadine | None | 43 | $2,006 | $47 |
| Propranolol | None | 60 | $779 | $13 |
See all 9 drugs
| Rytary | Parkinson's | 12 | $20,741 | $1,728 |
| Carbidopa-Levodopa | None | 124 | $3,046 | $25 |
| Carbidopa-Levodopa Er | None | 59 | $2,931 | $50 |
| Amantadine | None | 43 | $2,006 | $47 |
| Propranolol | None | 60 | $779 | $13 |
| Donepezil | None | 43 | $541 | $13 |
| Primidone | None | 17 | $373 | $22 |
| Gabapentin | None | 12 | $351 | $29 |
| Topiramate | None | 11 | $108 | $10 |
Year by year
| 2024 | 475 | 157 | 0% (0) | 7% | $108,329 |
| 2023 | 1,515 | 253 | None | 14% | $722,784 |
| 2022 | 2,229 | 292 | None | 12% | $967,006 |
| 2021 | 1,254 | 228 | None | 14% | $554,143 |
| 2020 | 265 | 88 | 0% (0) | 9% | $40,155 |
| 2019 | 361 | 70 | 0% (0) | 9% | $46,580 |
| 2018 | 84 | 32 | 0% (0) | None | $9,601 |
| 2016 | 11 | None | 0% (0) | 0% | $125 |
| 2015 | 70 | 30 | 0% (0) | 23% | $3,134 |
| 2014 | 28 | 15 | 0% (0) | None | $1,512 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Ingrezza | None | 24 | $183,464 | $7,644 |
| Nuplazid | Parkinson's psychosis | 22 | $167,639 | $7,620 |
| Rytary | Parkinson's | 61 | $122,577 | $2,009 |
| Carbidopa-Levodopa Er | None | 231 | $24,193 | $105 |
| Carbidopa-Levodopa | None | 388 | $23,925 | $62 |
| Neupro | None | 14 | $18,959 | $1,354 |
| Myrbetriq | None | 24 | $11,711 | $488 |
| Amantadine | None | 169 | $11,289 | $67 |
| Rivastigmine | None | 19 | $10,589 | $557 |
| Rasagiline Mesylate | None | 26 | $8,473 | $326 |
| Rivastigmine | None | 25 | $1,851 | $74 |
| Propranolol Hcl Er | None | 17 | $1,290 | $76 |
| Memantine | None | 19 | $1,066 | $56 |
| Propranolol | None | 45 | $1,039 | $23 |
| Gabapentin | None | 29 | $1,020 | $35 |
| Mirtazapine | None | 16 | $930 | $58 |
| Escitalopram | None | 27 | $746 | $28 |
| Glycopyrrolate | None | 20 | $639 | $32 |
| Donepezil | None | 24 | $615 | $26 |
| Clonazepam | None | 41 | $498 | $12 |
| Quetiapine | None | 13 | $435 | $33 |
| Orphenadrine Citrate Er | None | 17 | $421 | $25 |
| Primidone | None | 15 | $387 | $26 |
| Baclofen | None | 16 | $306 | $19 |
| Pramipexole Dihydrochloride | None | 14 | $229 | $16 |
| Ropinirole | None | 18 | $209 | $12 |
| Trazodone | None | 12 | $182 | $15 |
| Topiramate | None | 21 | $125 | $6 |
2022: 39 drugs
| Austedo | None | 46 | $246,191 | $5,352 |
| Ingrezza | None | 26 | $186,063 | $7,156 |
| Nuplazid | Parkinson's psychosis | 23 | $157,928 | $6,866 |
| Rytary | Parkinson's | 65 | $114,592 | $1,763 |
| Carbidopa-Levodopa Er | None | 385 | $31,646 | $82 |
| Neupro | None | 25 | $31,417 | $1,257 |
| Carbidopa-Levodopa | None | 523 | $31,231 | $60 |
| Azilect | None | 14 | $20,593 | $1,471 |
| Nuedexta | None | 14 | $19,150 | $1,368 |
| Amantadine | None | 221 | $16,307 | $74 |
| Rasagiline Mesylate | None | 16 | $8,213 | $513 |
| Myrbetriq | None | 18 | $7,920 | $440 |
| Rivastigmine | None | 14 | $6,545 | $467 |
| Carbidopa | None | 15 | $5,044 | $336 |
| Propranolol Hcl Er | None | 26 | $2,301 | $88 |
| Memantine | None | 28 | $2,163 | $77 |
| Orphenadrine Citrate Er | None | 46 | $2,143 | $47 |
| Gabapentin | None | 39 | $2,083 | $53 |
| Selegiline | None | 11 | $1,482 | $135 |
| Baclofen | None | 11 | $1,381 | $126 |
| Mirtazapine | None | 21 | $1,280 | $61 |
| Midodrine | None | 11 | $1,218 | $111 |
| Rivastigmine | None | 24 | $1,016 | $42 |
| Modafinil | None | 23 | $967 | $42 |
| Donepezil | None | 55 | $963 | $18 |
| Clonazepam | None | 109 | $947 | $9 |
| Propranolol | None | 44 | $901 | $20 |
| Glycopyrrolate | None | 32 | $616 | $19 |
| Primidone | None | 24 | $550 | $23 |
| Escitalopram | None | 21 | $458 | $22 |
| Pyridostigmine | None | 15 | $443 | $30 |
| Donepezil Hcl Odt | None | 14 | $352 | $25 |
| Pramipexole Dihydrochloride | None | 12 | $328 | $27 |
| Doxepin | None | 15 | $277 | $18 |
| Quetiapine | None | 30 | $231 | $8 |
| Zonisamide | None | 12 | $230 | $19 |
| Topiramate | None | 31 | $194 | $6 |
| Trihexyphenidyl | None | 15 | $102 | $7 |
| Trazodone | None | 11 | $61 | $6 |
2021: 24 drugs
| Ingrezza | None | 25 | $174,797 | $6,992 |
| Austedo | None | 30 | $130,826 | $4,361 |
| Rytary | Parkinson's | 46 | $63,346 | $1,377 |
| Neupro | None | 24 | $30,928 | $1,289 |
| Carbidopa-Levodopa | None | 294 | $19,651 | $67 |
| Nuedexta | None | 13 | $18,229 | $1,402 |
| Carbidopa-Levodopa Er | None | 174 | $14,358 | $83 |
| Amantadine | None | 152 | $10,795 | $71 |
| Memantine | None | 25 | $1,603 | $64 |
| Orphenadrine Citrate Er | None | 33 | $1,363 | $41 |
| Rivastigmine | None | 19 | $1,019 | $54 |
| Propranolol Hcl Er | None | 13 | $1,012 | $78 |
| Propranolol | None | 31 | $917 | $30 |
| Modafinil | None | 14 | $652 | $47 |
| Ropinirole | None | 13 | $614 | $47 |
| Glycopyrrolate | None | 16 | $608 | $38 |
| Gabapentin | None | 20 | $542 | $27 |
| Donepezil Hcl Odt | None | 23 | $430 | $19 |
| Clonazepam | None | 42 | $427 | $10 |
| Primidone | None | 19 | $410 | $22 |
| Topiramate | None | 23 | $241 | $10 |
| Doxepin | None | 13 | $203 | $16 |
| Duloxetine | None | 11 | $164 | $15 |
| Trihexyphenidyl | None | 12 | $84 | $7 |
2020: 4 drugs
| Carbidopa-Levodopa | 67 | $3,382 | $50 |
| Carbidopa-Levodopa Er | 21 | $1,601 | $76 |
| Amantadine | 11 | $973 | $88 |
| Clonazepam | 25 | $325 | $13 |
2019: 10 drugs
| Rytary | Parkinson's | 13 | $8,099 | $623 |
| Carbidopa-Levodopa | None | 93 | $4,423 | $48 |
| Selegiline | None | 23 | $4,286 | $186 |
| Carbidopa-Levodopa Er | None | 36 | $3,890 | $108 |
| Amantadine | None | 20 | $3,102 | $155 |
| Fludrocortisone Acetate | None | 15 | $254 | $17 |
| Primidone | None | 13 | $172 | $13 |
| Sertraline | None | 20 | $130 | $7 |
| Clonazepam | None | 22 | $119 | $5 |
| Quetiapine | None | 18 | $77 | $4 |
2018: 2 drugs
| Amantadine | 12 | $1,626 | $136 |
| Carbidopa-Levodopa | 15 | $966 | $64 |
2015: 1 drug
| Prednisone | 15 | $54 | $4 |
Money from drug and device companies
$1,093 in 2025
| 2025 | 1 | 6 | None | $1,093 |
| 2024 | 1 | 1 | None | $21 |
| 2022 | 5 | 9 | None | $722 |
| 2021 | 1 | 6 | None | $1,143 |
| 2020 | 3 | 4 | None | $343 |
| 2019 | 7 | 30 | None | $2,769 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Vercise | $1,093 | 6 payments
|
See all 6 published payments
| Boston Scientific | Travel · 2025-12-04 | Vercise | $105 |
| Boston Scientific | Meals · 2025-09-06 | Vercise | $195 |
| Boston Scientific | Travel · 2025-09-06 | Vercise | $21 |
| Boston Scientific | Meals · 2025-09-05 | General - Dbs | $111 |
| Boston Scientific | Travel · 2025-09-05 | Vercise | $333 |
| Boston Scientific | Travel · 2025-09-05 | Vercise | $329 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $21
| Abbott Laboratories | Infinity | $21 | 1 payment
|
2022: $722
| Abbott Laboratories | Infinity | $279 | 2 payments
|
| Insightec | Exablate | $149 | 1 payment
|
| Boston Scientific | General - Dbs | $145 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $134 | 4 payments
|
| Neurocrine Biosciences | Ongentys | $15 | 1 payment
|
2021: $1,143
| Boston Scientific | Vercise | $1,143 | 6 payments
|
2020: $343
| Kyowa Kirin | Nourianz | $186 | 2 payments
|
| US WorldMeds | Xadago | $139 | 1 payment
|
| Boston Scientific | General - Dbs | $18 | 1 payment
|
2019: $2,769
| Medtronic USA | Activa | $1,757 | 21 payments
|
| US WorldMeds | Myobloc | $321 | 2 payments
|
| AbbVie | Duopa | $218 | 2 payments
|
| Boston Scientific | Vercise | $153 | 2 payments
|
| Abbott Laboratories | Eon Family of Scs Ipgs | $132 | 1 payment
|
| Adamas Pharmaceuticals | Gocovri | $120 | 1 payment
|
| Lundbeck | Northera | $69 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1386063808
- Licence
- CA A159938, MA 1015812, NY 290159California A159938: Current · expires 2026-12-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084B0040X (2084B0040X); Neurology (2084N0400X)
- Mailing address
- 60 Fenwood Rd Fl 4, Boston, MA, 02115
- NPI first listed
- 2014-04-11
- NPI last updated
- 2023-12-22
- NPI record certified
- 2023-12-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 710 W 168th St, New York, NY, 10032 · 300 Pasteur Dr, Stanford, CA, 94305 · 355 Bard Ave, Staten Island, NY, 10310